TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.

Jian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.